Results 41 to 50 of about 8,348 (154)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

Retrovirology, 2011
Background HIV-2 is endemic in West Africa and has spread throughout Europe. However, the alternatives for HIV-2-infected patients are more limited than for HIV-1.
Damond Florence, Collin Gilles, Storto Alexandre, Charpentier Charlotte, Delelis Olivier, Ni Xiao-Ju, Descamps Diane, Mouscadet Jean-François   +7 more
doaj   +1 more source

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2764-2776, August 2026.
Aims While pregnancy‐related changes in phase I enzyme activity are well‐documented, less is known about the impact on phase II enzymes. This study aimed to test the hypothesis that changes in the pharmacokinetics (PK) of uridine 5′‐diphosphoglucuronosyltransferase (UGT) substrates during pregnancy result from altered enzyme expression or activity ...
William Saffaf, Ymke van der Velde, Paul R. V. Malik, Jelmer R. Prins, Sanne J. Gordijn, Daan J. Touw, Paola Mian   +6 more
wiley   +1 more source

Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women

Infectious Disease Reports, 2017
We conducted a retrospective study in a general hospital in Buenos Aires, Argentina (2009-2015) aimed at evaluating outcomes in HIV-infected pregnant women (HIPW), who were prescribed raltegravir (RAL)- containing antiretroviral therapy (ART). A total of
Diego M. Cecchini, Marina G. Martinez, Laura M. Morganti, Claudia G. Rodriguez   +3 more
doaj   +1 more source

Identification of Influenza PA_N Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening

Molecules, 2021
Structural and biochemical studies elucidate that PAN may contribute to the host protein shutdown observed during influenza A infection. Thus, inhibition of the endonuclease activity of viral RdRP is an attractive approach for novel antiviral therapy. In
Chao Zhang, Junjie Xiang, Qian Xie, Jing Zhao, Hong Zhang, Erfang Huang, Pangchui Shaw, Xiaoping Liu, Chun Hu   +8 more
doaj   +1 more source

Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aim Human T‐Lymphotropic virus type 1 (HTLV‐1) infection can lead to HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating chronic neurological disease characterized by progressive lower limb spasticity and autonomic dysfunction.
Meygol Mirzaei Rezaei, Mahdi Khosravi Nia, Kasra Allaei Rouzbahani, Maryam Kazemi, Negar Asghari Hosori, Mehdi Norouzi, Farzaneh Sotoudegan, Narges Eslami, Negar Ariamand, Vahid Shahnavaz, Arash Letafati, Sayed‑Hamidreza Mozhgani   +11 more
wiley   +1 more source

Raltegravir: molecular basis of its mechanism of action

European Journal of Medical Research, 2009
Integration of the HIV-1 viral DNA generated by reverse transcription of the RNA genome into the host cell chromosomes is a key step of viral replication, catalyzed by the viral integrase.
Mouscadet Jean-François, Tchertanov Luba   +1 more
doaj   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem of ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, Volume 27, Issue 7, Page 1132-1143, July 2026.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Infection and Drug Resistance, 2010
Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj